Rage experienced during perimenopause, a distinct and distressing symptom, is not adequately recognized or studied within clinical guidelines, according to medical experts.
Existing clinical guidance, such as the 2018 Menopause Society consensus guidelines on perimenopausal depression, directs clinicians to screen for and treat depressive symptoms. However, these guidelines do not specifically address or offer protocols for perimenopausal rage. Research that does measure irritability often includes it as part of broader anxiety measures, alongside nervousness and fearfulness, rather than examining it as a standalone clinical issue.
This lack of specific attention means that women experiencing intense rage—symptoms described as severe enough to cause significant life disruptions, such as leaving a job or avoiding career advancements—do not have a clear clinical pathway for treatment. Researchers are beginning to investigate this phenomenon, with a federally funded clinical trial at the University of North Carolina focusing on the neurophysiology of irritability during perimenopause. This trial acknowledges that many women with affective symptoms during this phase report irritability as their primary concern, rather than depression.
Experts advocate for perimenopausal rage to receive the same level of serious consideration and dedicated research now being applied to other menopause-related symptoms. The current lack of a diagnostic category, specific guidelines, or even a recognized name for perimenopausal rage on its own terms leaves a significant gap in understanding and treating this symptom.